

Balazs Acs

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2860645/balazs-acs-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

667
citations

14
h-index

25
g-index

47
ext. papers

1,093
ext. citations

6.3
avg, IF

4.54
L-index

#	Paper	IF	Citations
36	Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. <i>Cancers</i> , 2022 , 14, 2615	6.6	2
35	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. <i>Npj Breast Cancer</i> , 2021 , 7, 144	7.8	0
34	Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group. <i>Biomolecules</i> , 2021 , 11,	5.9	3
33	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 808-819	9.7	95
32	Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. <i>Cancers</i> , 2021 , 13,	6.6	5
31	Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer. <i>ESMO Open</i> , 2021 , 6, 100076	6	0
30	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5557-5565	12.9	6
29	A new tool for technical standardization of the Ki67 immunohistochemical assay. <i>Modern Pathology</i> , 2021 , 34, 1261-1270	9.8	4
28	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. <i>Scientific Reports</i> , 2021 , 11, 2809	4.9	2
27	Predicting Molecular Phenotypes from Histopathology Images: A Transcriptome-Wide Expression-Morphology Analysis in Breast Cancer. <i>Cancer Research</i> , 2021 , 81, 5115-5126	10.1	1
26	What do we still need to learn on digitally assessed biomarkers?. <i>EBioMedicine</i> , 2021 , 70, 103520	8.8	0
25	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021 , 13,	6.6	2
24	Improved breast cancer histological grading using deep learning. <i>Annals of Oncology</i> , 2021 ,	10.3	5
23	Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 161-175	4.4	16
22	Artificial intelligence as the next step towards precision pathology. <i>Journal of Internal Medicine</i> , 2020 , 288, 62-81	10.8	80
21	Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. <i>Clinical Cancer Research</i> , 2020 , 26, 1126-1134	12.9	29
20	Next generation pathology: artificial intelligence enhances histopathology practice. <i>Journal of Pathology</i> , 2020 , 250, 7-8	9.4	11

19	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. <i>Laboratory Investigation</i> , 2020 , 100, 4-15	5.9	32
18	Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 28	7.8	7
17	Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9577-9577	2.2	3
16	An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. <i>Nature Communications</i> , 2019 , 10, 5440	17.4	28
15	Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. <i>Laboratory Investigation</i> , 2019 , 99, 107-117	5.9	56
14	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 2442-2449	12.9	51
13	Not Just Digital Pathology, Intelligent Digital Pathology. <i>JAMA Oncology</i> , 2018 , 4, 403-404	13.4	23
12	Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018 , 26, e79-e85	1.9	26
11	Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer. <i>Pathology and Oncology Research</i> , 2018 , 24, 115-127	2.6	12
10	LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 139-147	3.5	1
9	Breast carcinoma subtypes show different patterns of metastatic behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 275-283	5.1	41
8	Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?. <i>Human Pathology</i> , 2017 , 65, 31-40	3.7	14
7	Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. <i>Diagnostic Pathology</i> , 2017 , 12, 20	3	45
6	PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study. <i>Breast</i> , 2017 , 35, 69-77	3.6	18
5	AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. <i>Npj Breast Cancer</i> , 2016 , 2, 16033	7.8	29
4	The Petersen prognostic index revisited in Dukes B colon cancer--Inter-institutional differences. <i>Pathology Research and Practice</i> , 2016 , 212, 73-6	3.4	1
3	In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. <i>Diagnostic Pathology</i> , 2016 , 11, 61	3	5
2	Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study. <i>Diagnostic Cytopathology</i> , 2016 , 44, 466-71	1.4	8

1 Current State of ERG as Biomarker in Prostatic Adenocarcinoma. *Current Cancer Drug Targets*, **2015**, 15, 643-51 2.8 1